ABT
ABBOTT LABORATORIES
Healthcare • NYSE • CIK 0000001800
Loading...
Market Cap
$171.01B
P/E (TTM)
31.9x
Rev Growth (TTM)
+8.1%
Net Margin (TTM)
11.6%
FCF Yield (TTM)
4.6%
FCF Margin (TTM)
16.8%
Figures as of June 30, 2026
Filings
Primary-source SEC disclosures, read end-to-end — every figure traceable to its filing.
8-KAug 20262026-08-20source
10-Q2026 Q22026-07-28source
8-KEarnings2026-07-16source
10-Q2026 Q12026-04-29source
8-KApr 20262026-04-27source
What your agent reads
Investor Relations
Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.
IR decks — not catalogued
Company-published, not SEC-audited
Earnings
Q2
3 months ago
8-K releaseRevenue
$12.59B
+13.0%
Net Income
$928.00M
-47.8%
EPS
N/A
—
Most recent quarterly earnings snapshot
Cash Flow Health
Free Cash Flow8/8 positive
TTM$7.8B
Q2 '26
$2.0B+117%
Q1 '26
$916.0M-65%
FCF Margin
TTM16.8%
Q2 '2615.8%+93%
Sector: 0.7%Top 25%
OCF Margin
21.3%
OCF/NI1.83x
CapEx Coverage
4.8x
FCF Yield4.6%
FCF Growth (3Y)+13%
Cash Conversion Cycle
–
DSO: 64+DIO: 123−DPO: –
Cash flow trends & capital efficiency
Capital Allocation
Total Shareholder YieldTTM
TTM3.6%
Div Yield2.5%
+Buyback (TTM)1.1%
Dividend & Payout Metrics
Dividend Yield (TTM)2.5%
FCF Payout Ratio54.9%
Free Cash Flow (TTM)$7.8B
Stock Repurchases (TTM)$1.8B
Capital Return / FCF78.7%
Shares Outstanding (YoY)-0.6%↓ Buyback
Est. Dividends Paid (TTM)$4.3B
Shows how management rewards shareholders
Valuation Metrics
Price-to-EarningsTTM
31.9x
Volatile
8Q: 34.6x+1889%
Multiple expansion without fundamental improvement
High PEG ratio (4.0x) suggests expensive for growth
Valuation Lenses
Earnings
31.9x
vs – sector
Cash Flow
25.3x
EV/FCF vs –
Growth-Adj
4.0xPEG
Expensive for growth
Quality-Adj
4.3P/E per %ROIC
ROIC: 7.3%
Shareholder Returns
Dividend
2.5%
Buyback
1.1%
Total Yield
3.6%
Market Cap$171.01B
EV$198.02B
Multi-angle valuation analysis with sector context
Margins & Efficiency
ROIC 74th pctile
Profitability Cascade
Gross
56.6%
Operating
15.8%
Top 25% in sector
Net
11.6%
Margins Unknown
Return on Invested CapitalTTM
7.3%
Stable
-0.1% YoY8Q: 10.1%-8.1%
P25MedianP75
74th pctl (med: -7.4%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
11.4%
8Q: 14.2%
Asset Turnover
0.49x
8Q: 0.54x
Leverage (1+D/E)
1.64x
D/E: 0.64x
DuPont: 9.2% ≈ 7.3% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
3.90x
8Q:3.98x
-20.6%
Invested Cap Turn
0.78x
8Q:0.85x
-12.6%
CapEx Intensity
3.5%
8Q:3.9%
CapEx/Depreciation
0.60x
FCF vs Net Margin Gap+5.1 pts
Margin trends, ROIC, and capital efficiency
Balance Sheet & Solvency
ND/EBITDA 1.3x
Net Debt / EBITDA
1.3xNet Debt: $27.00B
Interest Coverage
9.6x
+Strong interest coverage: 9.6x
Leverage Metrics
Debt-to-Equity
0.64x
Balance sheet risk & solvency analysis
Related Research
3 related posts